EANO guidelines for the diagnosis and treatment of ependymal tumors

• Verfasst von: Rudà, Roberta [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Titel: EANO guidelines for the diagnosis and treatment of ependymal tumors
• Verf.angabe: Roberta Rudà, Guido Reifenberger, Didier Frappaz, Stefan M. Pfister, Anne Laprie, Thomas Santarius, Patrick Roth, Joerg Christian Tonn, Riccardo Soffietti, Michael Weller, Elizabeth Cohen-Jonathan Moyal
• Jahr des Originals: 2017
• Fussnoten: Published: 29 November 2017 ; Gesehen am 02.05.2018
• Titel Quelle: Enthalten in: Neuro-Oncology
• Jahr Quelle: 2018
• Band/Heft Quelle: 20(2018), 4, S. 445-456
• ISSN Quelle: 1523-5866
• DOI: doi:10.1093/neuonc/nox166
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1572532327

Abstract

Ependymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient population.The diagnosis and disease staging is performed by craniospinal MRI. Tumor classification is achieved by histological and molecular diagnostic assessment of tissue specimens according to the World Health Organization (WHO) classification 2016. Surgery is the crucial initial treatment in both children and adults. In pediatric patients with intracranial ependymomas of WHO grades II or III, surgery is followed by local radiotherapy regardless of residual tumor volume. In adults, radiotherapy is employed in patients with anaplastic ependymoma WHO grade III, and in case of incomplete resection of WHO grade II ependymoma. Chemotherapy alone is reserved for young children <12 months and for adults with recurrent disease when further surgery and irradiation are no longer feasible. A gross total resection is the mainstay of treatment in spinal ependymomas, and radiotherapy is reserved for incompletely resected tumors. Nine subgroups of ependymal tumors across different anatomical compartments (supratentorial, posterior fossa, spinal) and patient ages have been identified with distinct genetic and epigenetic alterations, and with distinct outcomes. These findings may lead to more precise diagnostic and prognostic assessments, molecular subgroup-adapted therapies, and eventually new recommendations pending validation in prospective studies.